论文部分内容阅读
目的:观察应用马来酸曲美布汀联合黛力新治疗肠易激综合症临床疗效。方法:选取75例我院收治的肠易激综合症患者作为研究对象,患者选取的时间为2014年9月至2015年12月,将患者分为对照组(n=35)和治疗组(n=40),对照组患者应用马来酸曲美布汀治疗,治疗组患者应用马来酸曲美布汀联合黛力新治疗,观察患者的临床治疗效果。结果:对照组治疗的总有效率为82.9%,研究组治疗的总有效为97.5%,对2组患者疗效对比分析(X~2=4.730,P<0.05),治疗前,对患者的焦虑状态和抑郁状态评分比较,差异不明显(P>0.05),治疗后,两组的焦虑、抑郁评分均明显降低,研究组患者的焦虑、抑郁状态改善优于对照组(P<0.05)。结论:马来酸曲美布汀、黛力新联合治疗肠易激综合症,缓解了患者的临床症状,改善了患者的焦虑、抑郁心理,治疗效果明显,是值得推广的治疗药物。
Objective: To observe the clinical efficacy of trimebutine maleate combined with Deanin in the treatment of irritable bowel syndrome. Methods: Seventy-five patients with irritable bowel syndrome (IBS) treated in our hospital were enrolled in this study. The patients were selected from September 2014 to December 2015. The patients were divided into control group (n = 35) and treatment group = 40). The patients in the control group were treated with trimebutine maleate. The patients in the treatment group were treated with Trimebutine maleate and Deanxit. The clinical effect of the treatment was observed. Results: The total effective rate of the control group was 82.9%, and the total effective rate of the study group was 97.5%. The comparison of the curative effect between the two groups (X ~ 2 = 4.730, P <0.05) Compared with the depression score, the difference was not significant (P> 0.05). After treatment, the scores of anxiety and depression in both groups were significantly decreased. The improvement of anxiety and depression in the study group was better than that in the control group (P <0.05). Conclusion: Trimebutine maleate and Deanxit have been used in the treatment of irritable bowel syndrome, which has alleviated the clinical symptoms, improved the anxiety and depression of patients, and has obvious curative effect and is worthy of promotion.